Cancer Metabolism Based Therapeutics Market – Scope and Opportunities Analysis 2018 – 2026
According
to the study published in the Journal of Cancer Biology and Therapy,
2013, the controversial discovery of the 20th century by Otto
Warburg led to study of metabolic activity in cancerous tissue, which
increases the amount of production of lactate from glucose by tenfold
under aerobic condition. This has revealed that heterogeneity is
developed at cellular level leading to proliferation of cancerous
cells due to increased metabolism rate. Cancer metabolism is based on
the principle of cancer cells, which alter the metabolism of glucose
and glutamine for the synthesis of lipids, nucleotides, fatty acids,
and proteins that helps to proliferate cancer cells. It results in
inhibition of various metabolic pathways, such as the citric acid
cycle, glucose, mitochondrial respiration, and glutamine utilization.
Limited options of cancer metabolism targeting therapies are expected
provide potential opportunities for development of novel cancer
metabolism-based therapeutics in the near future.
Request
For Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/961
Global
Cancer Metabolism Based Therapeutics Market Taxonomy
On
the basis of drug and indication, cancer metabolism-based
therapeutics market segmented into two categories
By
Drug –
-
CPI-613
-
Enasidenib
By
Indication –
-
Acute Myeloid Leukemia (AML)
-
Myelodysplastic Syndromes (MDS)
-
Metastatic Renal Cell Carcinoma
-
Melanoma
-
Others
Targeting
cancer metabolism condition represents a potential opportunity to
develop novel drugs to treat multiple cancer types, which is expected
to boost the growth of cancer metabolism-based therapeutics
market
Rafael
pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017,
which is an anti-cancer compound - Altered Energy Metabolic Directed
(AEMD) drug specifically designed to target the mitochondrial
tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being
evaluated in clinical trial phase II. The Food and Drug
Administration (FDA) designated CPI-613 as an orphan drug for the
treatment of pancreatic cancer, acute myeloid leukemia (AML), and
Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as
an orphan drug designation for MYC amplified lymphoma/Burkitt
lymphoma and T-cell lymphoma in near future. Therefore, offering
orphan drug to the cancer patients would help to gain more value and
share for cancer metabolism based therapeutics market.
Increasing
incidence of cancer is expected to fuel the growth of cancer
metabolism based therapeutics market
According
to the American Cancer Society (ACS), approximately 53,670 people are
expected be diagnosed with pancreatic cancer and approximately 43,090
people are expected to die due to pancreatic cancer in the U.S in
2017. As per the ACS, pancreatic cancer accounts for around 3% of all
cancers and around 7% of all cancer deaths in the U.S. Moreover,
according to Cancer Research UK, approximately 3,072 new cases were
diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths
were occurred in 2014.
According
to National Cancer Institute, in the U.S, approximately 21,380 (1.3%)
new cases and approximately 10,590 deaths due to acute myeloid
leukemia (AML) are estimated in 2017. An increasing number of cancer
cases among people is expected to generate demand for new
therapeutics, which helps to target cancer metabolism condition, in
turn fueling the growth of cancer metabolism-based therapeutics
market in near future.
The
major key players in of cancer metabolism-based therapeutics market
include Calithera Biosciences, Inc., Celgene Corporation, Agios
Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and
AstraZeneca.
Click
to read more on Cancer
Metabolism Based Therapeutics Market
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment